Capital Advisors Ltd’s Foghorn Therapeutics FHTX Stock Holding History

Capital Advisors Ltd’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7	Closed	–	–	1470
2024 Q1	$0	Buy	+7	New	+$39	﹤0.01%	1418

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Capital Advisors Ltd's FHTX Position: Q2 2024 in Review

Capital Advisors Ltd sold out of Foghorn Therapeutics (FHTX) in Q2 2024, closing a stake of 7 shares.

Capital Advisors Ltd first reported a position in FHTX in Q1 2024 and held it in 1 quarter. The position peaked at $0 in Q1 2024. 72 funds tracked by Wall St. Rank hold FHTX as of Q2 2024.

Capital Advisors Ltd reported no remaining Foghorn Therapeutics position as of Q2 2024 after selling out during the quarter.
Capital Advisors Ltd sold 7 Foghorn Therapeutics shares in Q2 2024.
Capital Advisors Ltd first reported a position in Foghorn Therapeutics in Q1 2024 and held it in 1 quarter.
Capital Advisors Ltd's Foghorn Therapeutics position peaked at $0 in Q1 2024.
72 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2024.

Based on Capital Advisors Ltd's 13F filing for Q2 2024, filed 25 Jul 2024.